Meningoradiculitis due to varicella zoster virus reactivation in a patient treated with ixekizumab
- 1 October 2020
- journal article
- research article
- Published by Elsevier BV in Annales de Dermatologie et de Vénéréologie
- Vol. 147 (10), 667-671
- https://doi.org/10.1016/j.annder.2020.04.020
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Clinical Features of Varicella-Zoster Virus InfectionViruses, 2018
- Long‐term safety profile of ixekizumab in patients with moderate‐to‐severe plaque psoriasis: an integrated analysis from 11 clinical trialsJournal of the European Academy of Dermatology and Venereology, 2018
- The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis PathogenesisClinical Reviews in Allergy & Immunology, 2018
- Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)Journal of the American Academy of Dermatology, 2017
- Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasisBritish Journal of Dermatology, 2017
- Ixekizumab for the Treatment of Psoriasis: A Review of Phase III TrialsDermatology and Therapy, 2016
- Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid ArthritisThe Journal of Rheumatology, 2015
- Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatmentJournal of the American Academy of Dermatology, 2014
- Neurological complications of varicella zoster virus reactivationCurrent Opinion in Neurology, 2014
- Immunity to infection in IL‐17‐deficient mice and humansEuropean Journal of Immunology, 2012